A role for lysosomal phospholipase A2 in drug induced phospholipidosis

Akira Abe; Miki Hiraoka; James A Shayman

doi:10.2174/187231207779814292

A role for lysosomal phospholipase A2 in drug induced phospholipidosis

Drug Metab Lett. 2007 Jan;1(1):49-53. doi: 10.2174/187231207779814292.

Authors

Akira Abe¹, Miki Hiraoka, James A Shayman

Affiliation

¹ University of Michigan Medical Center, Department of Internal Medicine, Division of Nephrology, 1150 West Medical Center Drive, Ann Arbor, MI 48109-0676, USA. aabe@umich.edu

PMID: 19356018
DOI: 10.2174/187231207779814292

Abstract

Many therapeutic drugs currently in use are cationic amphiphiles. These cationic amphiphilic drugs (CADs) induce phospholipidosis in humans and experimental animals. The recent study shows that CAD-induced cellular phospholipidosis is linked to the impairment of phospholipid catabolism by inhibition of lysosomal phospholipase A2 activity.

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review

MeSH terms

Animals
Cations
Drug-Related Side Effects and Adverse Reactions*
Humans
Lipidoses / chemically induced*
Lipidoses / physiopathology
Lysosomes / enzymology
Pharmaceutical Preparations / chemistry
Phospholipase A2 Inhibitors*
Phospholipids / metabolism
Surface-Active Agents / adverse effects
Surface-Active Agents / chemistry

Substances

Cations
Pharmaceutical Preparations
Phospholipase A2 Inhibitors
Phospholipids
Surface-Active Agents